Background. Patients with peripheral vascular disease (PVD) undergo a clinical course that can be complicated by cardiovascular events occurring in several areas of the circulation. Methods and Results. In the present study we investigated the ability of picotamide, a substance that inhibits platelet thromboxane A2 (TxA2) synthase and antagonizes TxA2 receptors, to reduce cardiovascular complications in PVD patients. The study was double blind and placebo controlled. After a 1-month run-in period, 2,304 patients were randomly allocated to either placebo or picotamide (300 mg t.i.d.) and followed for 18 months. Major and minor events were analyzed. Results of an ''intention-to-treat analysis'' were that patients on picotamide suffered 45 major events (3.9%) and 77 minor events (6.7%), whereas those taking placebo suffered 52 major (4.5%) and ''minor events (8.6%). There was borderline statistical difference between the two groups with respect to the sum of the major and minor events (risk reduction, 18.9%; p=0.056, log-rank test). Results of an ''on-treatment'' analysis were that patients on picotamide suffered 40 major (3.8%) and 66 minor events (6.3%), whereas those taking placebo suffered 45 major (4.2%) and 95 minor events (8.9%). The sum of both major and minor events was 106 (10.1%) in the picotamide group and 140 (13.1%) in the placebo group. This difference was significant (risk reduction, 23%; p=0.029, log-rank test). Conclusions. The results of this study indicate that picotamide reduces cardiovascular complications in PVD patients. The apparently low effect of this drug in reducing major events suggests that further studies be made with picotamide in PVD patients who are at high risk of cardiovascular complications so as to further assess its clinical efficacy.

EFFECT OF PICOTAMIDE ON THE CLINICAL PROGRESSION OF PERIPHERAL VASCULAR-DISEASE - A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY / F., Balsano; Violi, Francesco; F., Aguglia; G. l., Lenzi; P. l., Prati; Rasura, Maurizia; G., Fieschi; E., Genazzani; A., Libretti; G. c., Nenci; Carlucci, Margherita; G., Leproux; S., Parisi; F., Folino; S., Vitale; S., Scaffidi; S., Delle Donne; A., Persiani; A., Longoni; M., Maderna. - In: CIRCULATION. - ISSN 0009-7322. - 87:5(1993), pp. 1563-1569.

EFFECT OF PICOTAMIDE ON THE CLINICAL PROGRESSION OF PERIPHERAL VASCULAR-DISEASE - A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY

VIOLI, Francesco;RASURA, Maurizia;CARLUCCI, Margherita;
1993

Abstract

Background. Patients with peripheral vascular disease (PVD) undergo a clinical course that can be complicated by cardiovascular events occurring in several areas of the circulation. Methods and Results. In the present study we investigated the ability of picotamide, a substance that inhibits platelet thromboxane A2 (TxA2) synthase and antagonizes TxA2 receptors, to reduce cardiovascular complications in PVD patients. The study was double blind and placebo controlled. After a 1-month run-in period, 2,304 patients were randomly allocated to either placebo or picotamide (300 mg t.i.d.) and followed for 18 months. Major and minor events were analyzed. Results of an ''intention-to-treat analysis'' were that patients on picotamide suffered 45 major events (3.9%) and 77 minor events (6.7%), whereas those taking placebo suffered 52 major (4.5%) and ''minor events (8.6%). There was borderline statistical difference between the two groups with respect to the sum of the major and minor events (risk reduction, 18.9%; p=0.056, log-rank test). Results of an ''on-treatment'' analysis were that patients on picotamide suffered 40 major (3.8%) and 66 minor events (6.3%), whereas those taking placebo suffered 45 major (4.2%) and 95 minor events (8.9%). The sum of both major and minor events was 106 (10.1%) in the picotamide group and 140 (13.1%) in the placebo group. This difference was significant (risk reduction, 23%; p=0.029, log-rank test). Conclusions. The results of this study indicate that picotamide reduces cardiovascular complications in PVD patients. The apparently low effect of this drug in reducing major events suggests that further studies be made with picotamide in PVD patients who are at high risk of cardiovascular complications so as to further assess its clinical efficacy.
1993
cardiovascular disease; antiplatelet therapy; vascular disease; peripheral; thromboxane
01 Pubblicazione su rivista::01a Articolo in rivista
EFFECT OF PICOTAMIDE ON THE CLINICAL PROGRESSION OF PERIPHERAL VASCULAR-DISEASE - A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY / F., Balsano; Violi, Francesco; F., Aguglia; G. l., Lenzi; P. l., Prati; Rasura, Maurizia; G., Fieschi; E., Genazzani; A., Libretti; G. c., Nenci; Carlucci, Margherita; G., Leproux; S., Parisi; F., Folino; S., Vitale; S., Scaffidi; S., Delle Donne; A., Persiani; A., Longoni; M., Maderna. - In: CIRCULATION. - ISSN 0009-7322. - 87:5(1993), pp. 1563-1569.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/379388
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 93
  • ???jsp.display-item.citation.isi??? 72
social impact